Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Invivyd, Inc.IVVD · Entity 721 | Director | May 19, 2026 | May 21, 2026 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director | June 14, 2023 | June 15, 2023 |
| Wave Life Sciences, Inc.WVE · Entity 4976 | Director · President and CEO | February 05, 2026 | February 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Invivyd, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2036-05-18 | Direct | 32,876 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 32,876 · Balance 32,876 F1: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
SQZ Biotechnologies Co
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13 | Direct | 39,875 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875 F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
Wave Life Sciences, Inc.
Report date February 05, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 275,520 |
Ending reported balance
After 2026-02-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-05 · Grant · Acquired 165,000 · Balance 286,000 F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030. Row 2 · 2026-02-09 · Sale · Disposed 10,480 · Balance 275,520 F2: On February 9, 2026, the reporting person sold 10,480 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2036-02-05 | Direct | 1,000,000 |
Reported balance
After 2026-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-05 · Grant · Acquired 1,000,000 · Balance 1,000,000 F3: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
F2: On February 9, 2026, the reporting person sold 10,480 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
F3: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 20:48 UTC | Invivyd, Inc. IVVD · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 32,876 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001193125-26-234660 · ownership.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,876 Underlying: Common Stock · 32,876 shares Expires 2036-05-18 F1 · derivative.exercise_date: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:02 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 10,480 | $13.45 | $140,956.00 |
DisclosureSEC source: 0001193125-26-047322 · ownership.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,520 F2 · kind: On February 9, 2026, the reporting person sold 10,480 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. Read SEC document |
| February 05, 2026 Filed Feb 12, 2026 02:02 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001193125-26-047322 · ownership.xml · derivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Ordinary Shares · 1,000,000 shares Expires 2036-02-05 F3 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030. Read SEC document |
| February 05, 2026 Filed Feb 12, 2026 02:02 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 165,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-047322 · ownership.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,000 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 21:07 UTC | Invivyd, Inc. IVVD · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001193125-25-215634 · ownership.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-09-21 F1 · derivative.exercise_date: This option was granted on September 22, 2025 and vests over a three-year period, with one-third of the shares subject to the grant vesting on the first anniversary of the grant date and 1/36th of the total shares subject to the grant vesting in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 22, 2025 Filed Aug 27, 2025 01:40 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 217,351 | $10.10 | $2,194,810.40 |
DisclosureSEC source: 0000950170-25-111567 · ownership.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2025. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.00 to $10.27 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2025 Filed Mar 8, 2025 02:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 48,059 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-25-035835 · ownership.xml · derivative · entry 4 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 48,059 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options reported in this Form 4 were set to expire on Monday, March 10, 2025. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F3 · derivative.exercise_date: These share options are fully vested and have an expiration date of Monday, March 10, 2025. Read SEC document |
| March 07, 2025 Filed Mar 8, 2025 02:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 120,966 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-25-035835 · ownership.xml · derivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 120,966 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options reported in this Form 4 were set to expire on Monday, March 10, 2025. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F3 · derivative.exercise_date: These share options are fully vested and have an expiration date of Monday, March 10, 2025. Read SEC document |
| March 07, 2025 Filed Mar 8, 2025 02:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 169,025 | $9.57 | $1,617,569.25 |
DisclosureSEC source: 0000950170-25-035835 · ownership.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 338,351 F1 · kind: The options reported in this Form 4 were set to expire on Monday, March 10, 2025. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $9.12 to $10.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2025 Filed Mar 8, 2025 02:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 169,025 | $2.48 | $419,182.00 |
DisclosureSEC source: 0000950170-25-035835 · ownership.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 507,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options reported in this Form 4 were set to expire on Monday, March 10, 2025. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. Read SEC document |
| February 04, 2025 Filed Feb 7, 2025 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0000950170-25-015681 · ownership.xml · derivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Ordinary Shares · 1,000,000 shares Expires 2035-02-04 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2029. Read SEC document |
| February 04, 2025 Filed Feb 7, 2025 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 121,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-015681 · ownership.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,351 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2026 through February 8, 2029. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 02:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-24-131691 · ownership.xml · derivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,778 Underlying: Ordinary Shares · 50,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 02:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 50,000 | $15.00 | $750,000.00 |
DisclosureSEC source: 0000950170-24-131691 · ownership.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,351 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 02:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 50,000 | $2.48 | $124,000.00 |
DisclosureSEC source: 0000950170-24-131691 · ownership.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2024. Read SEC document |
| November 15, 2024 Filed Nov 16, 2024 02:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 51,234 | $14.32 | $733,670.88 |
DisclosureSEC source: 0000950170-24-127740 · ownership.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,351 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.11 to $15.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 16, 2024 Filed Oct 19, 2024 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 90,474 | $15.00 | $1,357,110.00 |
DisclosureSEC source: 0000950170-24-115725 · ownership.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,585 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 22:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 48,366 | $5.78 | $279,555.48 |
DisclosureSEC source: 0000950170-24-100274 · ownership.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 359,059 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $5.68 to $5.94 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 00:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 1,008,600 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0000950170-24-012395 · ownership.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,008,600 Underlying: Ordinary Shares · 1,008,600 shares Expires 2034-02-05 F1 · derivative.exercise_date: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:39 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 39,875 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-23-037370 · doc4.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,875 Underlying: Common Stock · 39,875 shares Expires 2033-06-13 F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. Read SEC document |
| February 17, 2023 Filed Feb 18, 2023 01:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 771,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0000899243-23-005564 · doc4.xml · derivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,000 Underlying: Ordinary Shares · 771,000 shares Expires 2033-02-17 F3 · derivative.exercise_date: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. Read SEC document |
| February 16, 2023 Filed Feb 18, 2023 01:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 29,400 | $4.04 | $118,776.00 |
DisclosureSEC source: 0000899243-23-005564 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,425 F1 · kind: On February 16, 2023, the reporting person sold 29,400 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2023. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.03 to $4.17 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 25, 2022 Filed Jul 28, 2022 01:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0000899243-22-026926 · doc4.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Ordinary Shares · 180,000 shares Expires 2032-07-25 F1 · derivative.exercise_date: The option vests as to 50% of the shares on July 25, 2023 and 50% on July 25, 2024. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001209191-22-037486 · doc4.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 15, 2023 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 33,501 | $1.72 | $57,621.72 |
DisclosureSEC source: 0000899243-22-017135 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,825 F2 · kind: On May 5, 2022, the reporting person sold 33,501 ordinary shares solely to cover taxes associated with the vesting of the PSUs on May 4, 2022. These sales were made pursuant to a provision in the reporting person's PSU agreement that requires automatic sales of shares to cover tax withholding obligations. The sales are intended to comply with Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.72 to $1.74 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2022 Filed May 6, 2022 23:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 92,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017135 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,326 F1 · kind: On March 7, 2019, the reporting person received performance-based restricted share units ("PSUs"), convertible on a one-for-one basis into ordinary shares of the issuer upon vesting. On May 4, 2022, 50% of the PSUs vested upon the issuer's achievement of the PN Chemistry Milestone (as defined in the PSU agreement) following the issuer's recent WVE-004 data release, as certified by the issuer's compensation committee. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 33,150 | $2.32 | $76,908.00 |
DisclosureSEC source: 0000899243-22-007062 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,826 F1 · kind: On February 16, 2022, the reporting person sold 33,150 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2022. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $2.31 to $2.38 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:17 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0000899243-22-000666 · doc4.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Ordinary Shares · 600,000 shares Expires 2032-01-01 F1 · derivative.exercise_date: The option vests as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 10,500 | $0.00 Strike: $13.57 | $0.00 |
DisclosureSEC source: 0001209191-21-041533 · doc4.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-06-14 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 15, 2022 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders following the date of grant, in each case subject to the Reporting Person's continued service on the Board. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 11,205 | $10.57 | $118,436.85 |
DisclosureSEC source: 0000899243-21-007207 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,976 F2 · kind: On February 16, 2021, the reporting person sold 11,205 ordinary shares solely to cover taxes associated with the vesting of RSUs on February 15, 2021. These sales were made pursuant to a 10b5-1 Trading Plan. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.47 to $10.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0000899243-21-007207 · doc4.xml · derivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2031-02-01 F4 · derivative.exercise_date: The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007207 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,181 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 22:30 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 7,055 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-029980 · doc4.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,055 Underlying: Common Stock · 7,055 shares Expires 2030-10-28 F1 · derivative.exercise_date: The option vests and becomes exercisable on October 29, 2021. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-20-025614 · doc4.xml · derivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,778 Underlying: Ordinary Shares · 100,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 100,000 | $15.00 | $1,500,000.00 |
DisclosureSEC source: 0000899243-20-025614 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,181 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 100,000 | $2.48 | $248,000.00 |
DisclosureSEC source: 0000899243-20-025614 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 22:44 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-20-023540 · doc4.xml · derivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,778 Underlying: Ordinary Shares · 25,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 22:44 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 25,000 | $12.00 | $300,000.00 |
DisclosureSEC source: 0000899243-20-023540 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,181 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 22:44 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 25,000 | $2.48 | $62,000.00 |
DisclosureSEC source: 0000899243-20-023540 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · derivative · entry 6 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,778 Underlying: Ordinary Shares · 100,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 95,921 | $10.27 | $985,108.67 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · nonDerivative · entry 5 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,181 F4 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $9.77 to $10.77 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 4,079 | $10.91 | $44,501.89 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · nonDerivative · entry 4 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,102 F4 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.78 to $11.12 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 100,000 | $2.48 | $248,000.00 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · nonDerivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 43,068 | $10.26 | $441,877.68 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,181 F1 · kind: Consists of the sale of shares that were issued upon the vesting of restricted share units. The sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $9.77 to $10.77 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:56 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 4,509 | $10.82 | $48,787.38 |
DisclosureSEC source: 0000899243-20-018398 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,249 F1 · kind: Consists of the sale of shares that were issued upon the vesting of restricted share units. The sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.78 to $11.12 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 01:42 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 63,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000899243-20-007282 · doc4.xml · derivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Ordinary Shares · 63,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 23:23 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 11,451 | $7.85 | $89,890.35 |
DisclosureSEC source: 0000899243-20-005349 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,758 F1 · kind: On February 18, 2020, the reporting person sold 11,451 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2020. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.84 to $8.148 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:44 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-008404 · doc4.xml · derivative · entry 6 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,778 Underlying: Ordinary Shares · 50,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018. F6 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:44 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 1,763 | $46.00 | $81,098.00 |
DisclosureSEC source: 0000899243-19-008404 · doc4.xml · nonDerivative · entry 5 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,209 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018. F5 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $45.92 to $46.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:44 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 8,237 | $45.22 | $372,477.14 |
DisclosureSEC source: 0000899243-19-008404 · doc4.xml · nonDerivative · entry 4 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,972 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018. F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $44.90 to $45.88 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.